ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis

Nearly three years after Eli Lilly and Boehringer Ingelheim reported that Jardiance cut cardiovascular risks in a landmark outcomes trial named Empa-Reg, the study is still producing info about the drug. Now, based off a post-hoc analysis, investigators report that Jardiance cut the risk of kidney disease progression in the trial.